Clinical Trials Market Intelligence

best-value

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)

feature

 No Additional Benefits

Subscription Benefits:

  • PRO access to New Beroe LiVE*
  • Unlimited updates on the Report*
  • Supplier Watchlist for 3 suppliers*
  • Supplier Shortlisting Tool*

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)

feature

*These features will be unlocked on the new Beroe LiVE when it launches (Q3, 2020)

Are you looking for answers on Clinical Trials category?

Are you looking for answers on Clinical Trials category?

  • What are the key trends in Clinical Trials category?
  • Am I paying the right price?
  • Am I working with the right supplier?
  • What are the major challenges and risks in Clinical Trials industry?
  • How is Clinical Trials industry performing?

Over 50,000+ users trust Beroe

Report Coverage

  • Market Analysis
  • Engagement and Pricing Best Practices
  • Innovation Framework
  • Sustainability

Table of Contents

  1. Executive Summary/COVID-19 Update
  2. Executive Summary
  3. COVID– 19 Impact
  1. Market Analysis
  2. CRO
  3. Regional Analysis
  4. Drivers and Constraints
  5. Outsourcing Adoption
  6. Innovations
  7. Technology Trends
  1. Industry Best Practices
  2. EngagementModel
  3. Pricing Model
  1. Innovation Framework
  2. Technology Innovation
  1. Sustainability
  2. Sustainability

Want a more detailed personalised report?

Clinical Trials Global Market Outlook:

Market Growth:

Global Clinical Research Organisation Market - $42.3 billion in 2020E

CAGR – 7.6%

Market Drivers:

  • Increased focus of pharma on large molecule therapy, rare diseases, specialty treatment, point of care assays, and personalized therapy & devices
  • Greater investment in technology and data

CRO Market Size

  • The global CRO market was estimated at $42.3 billion in 2020E, and it is expected to grow at a CAGR of 7.6% percent to reach $49.9 billion by 2022F
  • This is due to the increased outsourcing seen from the pharmaceutical and biotechnology companies, with 85 percent comprised by the clinical segment
  • The focus of CROs have increased onto various post approval commercial offerings owing to increased development in technology and data analysis
  • Although spend on specialty focus, such as rare diseases, personalized medicines, and specialty oncology, has increased, the larger portfolio by spend size would continue to drive the programmatic CRO market

CRO Market Drivers

Cost Containment:

Pharmaceutical companies one of the major factors is to reduce costs, by lowering their internal capacities in manufacturing and R&D. This leads to expenses being diverted toward outsourcing, making CROs play an integral part of pharma to increase their productivity, access new capabilities, shift fixed to variable costs, and improve their global reach

RealWorld – Data and Analytics:

As regulators and payers place increasing importance on RWD, pharma is seen to partner with CRO, to support with predictive modeling, analytics, etc. This is driving CROs to either acquire or partner with specialists in this area

Emerging Markets:

The emerging markets of Brazil, China, Russia are witnessing increased trials, creating demand for regional CROs, with strong
regulatory knowledge

New areas of Research and Regulations:

The increased focus of pharma on large molecule therapy, rare diseases, specialty treatment, point of care assays, and personalized therapy & devices will require clinical trial testing and submission of data to the relevant regulatory authorities

Also, the depth of regulatory scrutiny has increased, such as early RWD collection and reporting every adverse events, driving increased clinical trials

Examples: Offshoring of HEOR, pharmacovigilance services to India offer cost saving of ~30–45 percent

Sustainability:

Pharma companies are highly focussed on enhancing sustainability by energy conservation, waste management and green manufacturing. Green Chemistry improves the efficiency of research and development and manufacturing practices, improving safety, saving money and lessening our impact on the environment.

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)

feature

Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.

x

COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)